Neuroprotective activity of citicoline in prophylactic injection in experiment
https://doi.org/10.25694/URMJ.2018.04.130
Abstract
Objective. To perform a comparative neurological assessment of neuroprotective activity of citicoline in a prophylactic and therapeutic injection on the model of focal brain ischemia in rats. Matherials and Methods. The study was performed on 51 male rats with weight 180-220 g. We studied the potential of preventative single injection and daily therapeutic injection of citicoline (2000 mg/kg) on the model of 60-minute intravasal occlusion of the left MCA Assessment of neurological deficit in all experimental groups was performed before ischemia and the next 5 days after using the 4-point Bederson scale and the McGraw Stroke Index scale with Ohno modifications. Results. Intravascular occlusion of the left MCA was followed by neurologic disorders of different severity in experimental animals of all groups. At the same time, daily (therapeutic) use of CDP-choline in the postischemic period was not followed by statistically significant improvement in neurological status in rats compared with control group. The most significant protective effect of citicoline, according to neurological test, was marked in cases with single prophylactic injection before ischemia. Conclusion. Prophylactic injection of citicoline possesses a pronounced neuroprotective activity in case of cerebral ischemia, which is manifested by significantly smaller number of cases with neurologic deficit and lethality of experimental animals in comparison with control group.
About the Authors
G. Z. Sufianova
ФГБОУ ВО Тюменский ГМУ Минздрава России
Russian Federation
Russian Federation
A. G. Shapkin
ФГБОУ ВО Тюменский ГМУ Минздрава России; ФГБУ Федеральный центр нейрохирургии Минздрава России
Russian Federation
Russian Federation
M. S. Khlestkina
ФГБОУ ВО Тюменский ГМУ Минздрава России
Russian Federation
Russian Federation
A. A. Sufianov
ФГБУ Федеральный центр нейрохирургии Минздрава России; ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Russian Federation
Russian Federation
References
1. Гусев Е.И., Скворцова В.И. Нейропротективная терапия ишемического инсульта. Нервные болезни. 2002; 1: 3-7.
2. Стаховская Л.В., Клочихина О.А., БогатыреваМ.Д., Коваленко В.В. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009-2010). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):4-10.
3. Суфианова Г.З., Шапкин А.Г. Повреждение нервной ткани: механизмы, модели, методы оценки. М: Издательство РАМН; 2014.
4. Суфианова Г.З., Усов Л.А., Суфианов А.А., Шапкин А.Г., Раевская Л.Ю. Защитное действие циклопентиладенозина на малоинвазивной модели острой фокальной ишемии головного мозга у крыс // Эксп. и клин. фарм. 2002; 65(1): 24-6.
5. Alvarez-Sabin J., Român G.C. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013; 3(3):1395-414.
6. Bustamante A., Giralt D., Garcia-Bonilla L. et al. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012; 123(2): 217-25.
7. Diederich K., Frauenknecht K., Minnerup J. et al. Citicoline enhances neuroregenerative processes after experimental stroke in rats. Stroke. 2012; 43(7): 1931-40.
8. Hurtado O., Moro M.A., Càrdenas A. et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis. 2005;18(2):
9. Мушба А.В., Иванова Д.С., Виноградов О.И. Влияние цитиколина на эффективность восстановительных мероприятий у больных с ишемическим инсультом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(2):71-75.
10. Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs. 2014; 28(3): 185-93.
11. Bederson J.B., Pitts L.H., Tsuji M. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17(3): 472-6.
12. McGraw C.P. Experimental cerebral infarction effects of pentobarbital in Mongolian gerbils. Arch Neurol. 1977;34(6): 334-6.
13. Ohno K., Ito U., Inaba Y. Regional cerebral blood flow and stroke index after left carotid artery ligation in the conscious gerbil. Brain Res. 1984; 297(1):151-7.
14. Cansev M., Minbay Z., Goren B. et al. Neuroprotective effects of uridine in a rat model of neonatal hypoxic-ischemic encephalopathy. Neurosci Lett. 2013;542: 6570.
15. Secades J.J., Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995; 17(Suppl B):1-54.
16. Cotroneo A.M., Castagna A., Putignano S. et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013; 8:131-7.
17. Mir C., Clotet J., Aledo R. et al. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Mol Neurosci. 2003;20(1): 53-60.
18. Koyuncuoglu T., Turkyilmaz M., Goren B. et al. Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats. Restor Neurol Neurosci. 2015;33(5):777-84.
19. von Kügelgen I., Hoffmann K. Pharmacology and structure of P2Y receptors. Neuropharmacology. 2016; 104:50-61.
Review
For citations:
Sufianova GZ, Shapkin AG, Khlestkina MS, Sufianov AA. Neuroprotective activity of citicoline in prophylactic injection in experiment. Ural Medical Journal. 2018;(7):83-88. (In Russ.) https://doi.org/10.25694/URMJ.2018.04.130
Views:
137
Email this article 